Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 1/20 | 0.54 |
| ▸ | NPBWR1 | P48145 | 9/20 | 0.53 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | MMP8 | P22894 | 1/20 | 0.51 |
| ▸ | MMP13 | P45452 | 1/20 | 0.51 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.48 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.48 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4157920 | 0.91 | RHEB (0.55) | RHEBNPBWR1MMP2MMP9MMP8 | |
| SCHEMBL4138826 | 0.91 | NPBWR1 (0.48) | RHEBNPBWR1DGAT1KCNH2MMP2 | |
| SCHEMBL4148421 | 0.88 | DGAT1 (0.57) | NPBWR1DGAT1KCNH2CHEK2SOAT1 | |
| SCHEMBL4147631 | 0.86 | NPBWR1 (0.50) | NPBWR1DGAT1KCNH2SIRT2SIRT1 | |
| SCHEMBL4160495 | 0.85 | MMP2 (0.71) | RHEBMMP2MMP9MMP8MMP13 | |
| SCHEMBL4149048 | 0.84 | RHEB (0.45) | RHEBMMP2MMP9MMP8MMP13 | |
| SCHEMBL13741764 | 0.84 | KDM4E (0.67) | RHEBMMP2MMP9MMP8MMP13 | |
| SCHEMBL4155027 | 0.83 | RHEB (0.47) | RHEBDGAT1KCNH2MMP2MMP9 | |
| SCHEMBL4148810 | 0.81 | DGAT1 (0.53) | NPBWR1DGAT1KCNH2SOAT1 | |
| SCHEMBL4159703 | 0.81 | NPBWR1 (0.56) | NPBWR1DGAT1KCNH2SOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940769-B2 | Biaryl benzoimidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-01-27 | — | — | US | claimed |
| EP-2054405-B1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAE WOONG PHARMA (KR) | 2013-09-18 | — | — | EP | claimed |
| US-20130217684-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-08-22 | — | — | US | claimed |
| US-20090209540-A1 | Novel Biaryl Benzolmidazole Derivatives and Pharmaceutical Composition Comprising The Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-08-20 | — | — | US | claimed |
| EP-2054405-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-05-06 | — | — | EP | claimed |
| WO-2008007900-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2008-01-17 | — | — | WO | claimed |
| US-8940769-B2 | Biaryl benzoimidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-01-27 | — | — | US | disclosed |
| EP-2054405-B1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAE WOONG PHARMA (KR) | 2013-09-18 | — | — | EP | disclosed |
| US-20130217684-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-08-22 | — | — | US | disclosed |
| US-8436022-B2 | Biaryl benzolmidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-05-07 | — | — | US | disclosed |
| US-20090209540-A1 | Novel Biaryl Benzolmidazole Derivatives and Pharmaceutical Composition Comprising The Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-08-20 | — | — | US | disclosed |
| EP-2054405-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008007900-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209540-A1 | Novel Biaryl Benzolmidazole Derivatives and Pharmaceutical Composition Comprising The Same | TRPV1, TRPV3, TRPV5 | RHEB 2148/4885NPBWR1 840/4885DGAT1 2497/4885 |
| US-20130217684-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | TRPV1, TRPV3, TRPA1 | RHEB 1405/4885NPBWR1 383/4885DGAT1 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.